| Literature DB >> 26819666 |
Vishnu Nayak Badavath1, İpek Baysal2, Gulberk Ucar2, Barij Nayan Sinha1, Venkatesan Jayaprakash1.
Abstract
A series of new 2-methoxy-4-(5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenolderivatives, 4-13, were synthesized and tested for their human MAO inhibitory activity. All the compounds were found to be selective and reversible toward hMAO-A except 4, a selective inhibitor of hMAO-B and 12, a nonselective inhibitor. Compound 7 was found to be a potent inhibitor of hMAO-A with Ki = 0.06 ± 0.003 μM and was having selectivity index of (SI = 1.02 × 10(-5)). It was found to be better than standard drug, Moclobemide (hMAO-A with Ki = 0.11 ± 0.01 μM) with selectivity index of SI = 0.049. Molecular docking simulation was carried out to understand the crucial interactions responsible for selectivity and potency.Entities:
Keywords: Human monoamine oxidase; enzyme inhibitors; molecular docking simulation; pyrazoline
Year: 2015 PMID: 26819666 PMCID: PMC4716609 DOI: 10.1021/acsmedchemlett.5b00326
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345